Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.0%

3 terminated/withdrawn out of 30 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

20%

6 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

15(51.7%)

Phase 2

6(20.7%)

Phase 3

5(17.2%)

N/A

2(6.9%)

Phase 4

1(3.4%)

29Total

Phase 1(15)

Phase 2(6)

Phase 3(5)

N/A(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT06468033Phase 3Active Not Recruiting

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Role: lead

NCT06290765Phase 4Withdrawn

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

Role: lead

NCT07734272Not ApplicableNot Yet Recruiting

Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative

Role: collaborator

NCT06665776Terminated

HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Role: lead

NCT04285086Phase 3Active Not Recruiting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Role: lead

NCT07521046Phase 1Not Yet Recruiting

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Role: collaborator

NCT07646821Phase 1Not Yet Recruiting

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

Role: collaborator

NCT04638439Phase 1Completed

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Role: lead

NCT07468916Phase 2Not Yet Recruiting

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Role: collaborator

NCT07047885Phase 1Recruiting

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Role: collaborator

NCT05482971Phase 2Active Not Recruiting

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Role: lead

NCT05481151Phase 3Active Not Recruiting

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Role: lead

NCT05485948Phase 2Active Not Recruiting

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Role: lead

NCT07053904Phase 1Enrolling By Invitation

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

Role: lead

NCT05522816Phase 1Completed

KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis

Role: lead

NCT06698861Phase 1Completed

A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers

Role: lead

NCT03165955Phase 1Completed

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Role: collaborator

NCT05231044Phase 3Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Role: lead

NCT05467553Phase 2Unknown

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

Role: collaborator

NCT05494528Not ApplicableUnknown

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Role: collaborator